1.09
+3.81%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $60.0m
- Last close × shares
- Volume
- 210.8k
- Shares, 19 Nov 2026
About Vivani Medical
From its filings with the US Securities and Exchange Commission
Vivani Medical is based in Alameda, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VANI. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $26.6m. At that date it held total assets of $39.4m and shareholders' equity of $15.7m.
Vivani Medical, Inc. (“Vivani,” the “Company,” “we,” “us,” “our” or similar terms) is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address leading causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients.
According to the U.S. Centers for Disease Control and Prevention, adherence is defined as the extent to which an individual’s behavior, including taking medications, corresponds to recommendations from a health care provider. An alarmingly high proportion of patients, approximately 50%, do not, or cannot, take their medicine as prescribed in the real world, a statistic that applies to both daily oral as well as weekly injectable medicines. For example, a recent study has shown that 64% of patients taking Wegovy® (semaglutide injection) discontinue treatment within the first year, a number that increases to 76% by the second year. Unfortunately, GLP-1 discontinuation may result in failure to achieve target outcomes and a quick reversal of the health benefits in the majority of patients.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2018
- Represents the information pertaining to Argus II product. $6.9m · 100.1%
Latest on Vivani Medical
Our reporting
Next results
Due on 1 Apr 2027. Analysts expect earnings of -0.09 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Vivani Medical's ticker?
Vivani Medical trades as VANI on its US listing, under ISIN US92854B1098.
What was Vivani Medical's last closing price?
1.09 on 19 Nov 2026. The figure is in USD and is never converted.
When does Vivani Medical next report results?
Results are expected on 12 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.